A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACI-19764 in Healthy Volunteers

The primary objective of this Phase 1 study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACI-19764 following the administration of single ascending doses and multiple ascending doses in healthy volunteers. This investigation is essential to establish the initial safety profile and characterize the drug's disposition and biological effects in humans.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers, including both male and female individuals. The participants belong to vulnerable populations and fall within the specified age ranges of 3 and 4 years.

This Phase 1, single-center, double-blind, randomized, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACI-19764. The investigation utilizes both single-ascending dose and multiple-ascending dose methodologies in healthy volunteers. The clinical sequence begins with a screening visit to determine eligibility. Following administration, participants undergo scheduled follow-up visits to monitor physiological responses and drug concentrations. The study concludes with an end-of-study visit. The total duration of participant involvement is determined by the specific dosing regimen assigned. Study termination may occur prematurely if specific safety criteria or protocol deviations are met.

The assessment of efficacy in this Phase 1 clinical trial involves the evaluation of parameters specific to healthy volunteers. No specific efficacy endpoints, measurement schedules, or analytical tools were provided in the source data.